
    
      The Investigators expect to assess outcomes of all patients who received Drug Coated Balloon
      Angioplasty treatment, which is a novel therapy as opposed to standard Drug Eluting Stent
      insertion, for all types of coronary artery disease from 01/01/2009 till 31/12/2015 in their
      center. The Investigators believe the number exceeds 1000 patients.

      The Investigators plan to collect demographic and procedural data from their existing data
      base. They will request up to date follow-up events from NICOR (National Institute for
      Cardiovascular Outcomes Research, UK) in 2017(data ending December 2016), by which time all
      patientswould have had minimum of 12 months follow up. The Investigators plan to incorporate
      these findings to their data set and report the comprehensive outcomes. Primary end point
      will be major adverse cardiac outcomes (MACE) defined as a composite of death, myocardial
      infarction and target vessel revascularisation. Secondary end points will be acute vessel
      closure and target lesion revascularisation. The Investigators also have a long term plan of
      requesting follow-up events from NICOR for up to 10 years, so they can report on long term
      outcomes of drug coated balloon treatment.
    
  